| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | Biomarker | disease | BEFREE | Metabotropic Glutamate Receptor 5 and 8 Modulate the Ameliorative Effect of Ultramicronized Palmitoylethanolamide on Cognitive Decline Associated with Neuropathic Pain. | 30970677 | 2019 | ||||
|
0.090 | GeneticVariation | disease | BEFREE | While these genetic variants in GRM5 were associated with cognitive impairments and right hippocampal volume reduction in schizophrenia, they did not affect protein expression. | 28405888 | 2018 | ||||
|
0.090 | Biomarker | disease | BEFREE | Targeting mGlu5 Metabotropic Glutamate Receptors in the Treatment of Cognitive Dysfunction in a Mouse Model of Phenylketonuria. | 29615849 | 2018 | ||||
|
0.090 | Biomarker | disease | BEFREE | α-synuclein interacts with PrP<sup>C</sup> to induce cognitive impairment through mGluR5 and NMDAR2B. | 28945221 | 2017 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | This correlated with a reduced amplitude of synaptic NMDAR currents, a lack of their mGluR5-activated long-term depression, and NMDAR/hippocampus dependent cognitive deficits. | 29062097 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | Accordingly, mGluR5 positive allosteric modulators show encouraging therapeutic potential in preclinical schizophrenia models, particularly for the treatment of cognitive dysfunctions against which currently available therapeutics are largely ineffective. | 26349010 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | MGlu5-dysfunctions are associated with profound cognitive deficits in humans, and mGlu5 has been targeted as a putative cognitive enhancer. | 27267685 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | Collectively, these data support and extend the role for the development of novel mGlu5 PAMs for the treatment of psychosis and cognitive deficits observed in individuals with schizophrenia. | 23965381 | 2013 | ||||
|
0.090 | Biomarker | disease | BEFREE | This absence causes loss of repression of metabotropic glutamate receptor 5 (mGluR5)-mediated pathways resulting in the behavioral and cognitive impairments associated with FXS. | 22397687 | 2012 |